Member Contact: Tony Sasse
Position: Managing Director
Industry: Biotech & Pharmaceuticals
At Snoretox, we have developed novel tetanus toxin based biotherapeutics for the treatment of conditions by the controlled increase of local muscle tone. These include Snoring, Obstructive Sleep Apnoea, Ectropion, cosmetic indications, anal incontinence, and neurological muscle disorders in animals and humans. Snoretox has previously demonstrated the ability to treat sleep apnea with tetanus toxin in an animal model of the disease, the British bulldog. The innovations we have made at Snoretox, were to develop and patent technologies and modifications of tetanus toxin that enables it to function in an individual that is vaccinated against tetanus, unlocking the immense therapeutic, cosmetic and veterinary potential of the tetanus toxin.